[HTML][HTML] Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo …
T Akizawa, M Iwasaki, T Otsuka, M Reusch… - Advances in Therapy, 2019 - Springer
Introduction This study evaluated efficacy and safety/tolerability of roxadustat, an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo …
T Akizawa, M Iwasaki, T Otsuka… - Advances in …, 2019 - pubmed.ncbi.nlm.nih.gov
Introduction This study evaluated efficacy and safety/tolerability of roxadustat, an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
[HTML][HTML] Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo …
T Akizawa, M Iwasaki, T Otsuka, M Reusch… - Advances in …, 2019 - ncbi.nlm.nih.gov
Methods In this phase 2, double-blind, 24-week study, NDD-CKD patients were randomized
to oral placebo or roxadustat (50, 70, or 100 mg) three times weekly (TIW) for 6 weeks …
to oral placebo or roxadustat (50, 70, or 100 mg) three times weekly (TIW) for 6 weeks …
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo …
T Akizawa, M Iwasaki, T Otsuka, M Reusch… - Advances in …, 2019 - europepmc.org
Methods In this phase 2, double-blind, 24-week study, NDD-CKD patients were randomized
to oral placebo or roxadustat (50, 70, or 100 mg) three times weekly (TIW) for 6 weeks …
to oral placebo or roxadustat (50, 70, or 100 mg) three times weekly (TIW) for 6 weeks …
[PDF][PDF] Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo …
TAMIT Otsuka, M Reusch - 2019 - d-nb.info
Introduction: This study evaluated efficacy and safety/tolerability of roxadustat, an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
[PDF][PDF] Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo …
TAMIT Otsuka, M Reusch - Adv Ther, 2019 - scienceopen.com
Introduction: This study evaluated efficacy and safety/tolerability of roxadustat, an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis …
[引用][C] Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo …
T Akizawa, M Iwasaki, T Otsuka, M Reusch… - Advances in …, 2019 - cir.nii.ac.jp
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients
Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial | CiNii …
Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial | CiNii …